arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GRAIL, Inc.

GRAL
$119.02 ▼ -24.64 (-17.15%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
5 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

GRAIL, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4B
Dividend Yield —
Revenue Growth 17.2% ↘
Op. Margin -382.0%
ROIC -16.7% ↗
FCF / Share $-8.16 ↗
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$147.17M
↑ +17.2% —
Net Income Profit after all expenses
$-408.35M
↑ +79.9% —
FCF / Share Free cash flow per share
$-8.16
↑ +55.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
0
Returns ↑
30
Cash Quality ↑
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 15 quarters